查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587468

抗心律不整药物市场规模、份额和趋势分析报告：按药物类别、给药途径、分销管道、地区和细分市场预测，2024-2030年

Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Beta Blockers, Sodium Channel Blockers), By Route of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

抗心律不整药物市场成长与趋势：

Grand View Research研究报告显示，预计到2030年，全球抗心律不整药物市场规模将达16.2亿美元，2024年至2030年复合年增长率为6.4%。

根据世界卫生组织 (WHO) 的数据，CVD 是全球第一大死因，每年导致约 1,790 万人死亡。

此外，人口老化也是市场扩张的主要因素。美国人口普查局报告称，到 2030 年，大约 20% 的美国人口将达到 65 岁或以上。这种人口结构的变化预计将导致心血管疾病（包括心律不整）的增加，以及抗心律不整药物的需求增加。随着年龄的增长，心臟病的风险会增加，需要持续的治疗和管理策略。这种趋势并非美国独有；许多已开发国家和开发中国家也出现了类似的人口变化，导致全球抗心律不整药物的需求增加。

最近的药物开发趋势进一步推动了市场成长。抗心律不整药物领域的研究和创新导致了新化合物和治疗方法的引入。例如，针对特定离子通道的新药物配方的开发提高了这些药物的功效和安全性。此外，个人化医疗和药物基因组学的进步为客製化治疗策略铺平了道路，这些策略可以根据个别患者的情况优化药物疗效。这些创新不仅改善了治疗结果，还促进了医疗保健专业人员采用抗心律不整疗法。

抗心律不整药物市场报告亮点

  • 按药物类别划分， β阻断剂细分市场在 2023 年占据最大销售份额，达到 34.7%。由于它能有效降低心率和控制血压，因此已成为治疗这些疾病的基石。
  • 依给药途径，口服製剂占最大销售份额，2023年约65.0%。口服製剂在治疗心房颤动和心室心搏过速等慢性疾病方面特别有吸引力，因为它们允许患者家用中自行进行治疗，无需进行侵入性手术或去医院就诊。
  • 从分销管道来看，2023年医院药局将占据全球抗心律不整药物市场的最大销售份额，约占55.0%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章抗心律不整药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 抗心律不整药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 抗心律不整药物市场：药物类别估计与趋势分析

  • 抗心律不整药物市场：药物类别仪表板
  • 抗心律不整药物市场：药品类别波动分析
  • 抗心律不整药物市场：按药物类别分類的收益
  • 钠通道阻断剂
  • 钾通道阻断剂
  • 钙离子通道阻断剂
  • 其他的

第五章 抗心律不整药物市场：给药途径估算与趋势分析

  • 抗心律不整药物市场：给药途径仪表板
  • 抗心律不整药物市场：给药途径变异分析
  • 按途径的收益
  • 口服
  • 胃肠外的
  • 其他的

第六章 抗心律不整药物市场：通路估算及趋势分析

  • 抗心律不整药物市场：通路仪表板
  • 按分销管道分類的收益
  • 医院药房
  • 零售药房
  • 其他的

第七章 抗心律不整药物市场：按药物类别分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2023年主要企业市场占有率分析
    • Pfizer
    • Novartis
    • Mylan
    • Baxter International
    • Sanofi
    • GlaxoSmithKline
    • Mayne Pharma
    • Upsher-Smith Laboratories
    • Amomed Pharma
    • Merck
Product Code: GVR-4-68040-479-7

Antiarrhythmic Drugs Market Growth & Trends:

The global antiarrhythmic drugs market size is anticipated to reach USD 1.62 billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030, according to a report by Grand View Research, Inc. This anticipated growth is driven by multiple interrelated factors, including the rising prevalence of cardiovascular diseases (CVDs), an aging global population, advancements in drug development, regulatory support, and government initiatives aimed at improving cardiovascular health.According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for approximately 17.9 million deaths annually.

Furthermore, the aging population is a significant factor contributing to market expansion. The U.S. Census Bureau reports that by 2030, approximately 20% of the U.S. population will be 65 years or older. This demographic shift is expected to lead to an increase in cardiovascular conditions, including arrhythmias, thereby heightening the demand for antiarrhythmic drugs. As people age, their risk of developing heart conditions increases, necessitating ongoing treatment and management strategies. This trend is not limited to the U.S.; many developed and developing nations are experiencing similar demographic changes, resulting in a global increase in demand for antiarrhythmic therapies.

Recent advancements in drug development are further propelling market growth. Research and innovation in the field of antiarrhythmic drugs have led to the introduction of novel compounds and therapeutic approaches. For instance, the development of new drug formulations that target specific ion channels has improved the efficacy and safety profiles of these medications. Moreover, advances in personalized medicine and pharmacogenomics are paving the way for tailored treatment strategies that optimize drug efficacy based on individual patient profiles. Such innovations not only enhance treatment outcomes but also encourage the adoption of antiarrhythmic therapies among healthcare providers.

Antiarrhythmic Drugs Market Report Highlights:

  • By drug class, the beta blockers segment accounted for the largest revenue share of 34.7% in 2023. Their efficacy in reducing heart rate and controlling blood pressure has made them a cornerstone in the treatment of these disorders.
  • Based on route of administration, the oral segment accounted for the largest revenue share of around 65.0% in 2023. Oral formulations allow patients to self-administer treatments at home, eliminating the need for invasive procedures or hospital visits, which can be particularly appealing in managing chronic conditions such as atrial fibrillation and ventricular tachycardia.
  • Based on distribution channels, the hospital pharmacies segment accounted for the largest revenue share of around 55.0% in global market for antiarrhythmic drugs in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class Outlook
    • 2.2.2. Route of Administration
    • 2.2.3. Distribution Channel
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antiarrhythmic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Cardiovascular Diseases
      • 3.2.1.2. Advancements in Drug Development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Drug Class Cost
      • 3.2.2.2. Competition from Alternative Therapies
  • 3.3. Antiarrhythmic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antiarrhythmic Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Antiarrhythmic Drugs Market: Drug Class Dashboard
  • 4.2. Antiarrhythmic Drugs Market: Drug Class Movement Analysis
  • 4.3. Antiarrhythmic Drugs Market by Drug Class, Revenue
  • 4.4. Sodium Channel Blockers
    • 4.4.1. Sodium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Potassium Channel Blockers
    • 4.5.1. Potassium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Calcium Channel Blockers
    • 4.6.1. Calcium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antiarrhythmic Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Antiarrhythmic Drugs Market: Route of Administration Dashboard
  • 5.2. Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
  • 5.3. Antiarrhythmic Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Parenteral
    • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antiarrhythmic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Antiarrhythmic Drugs Market: Distribution Channel Dashboard
  • 6.2. Antiarrhythmic Drugs Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antiarrhythmic Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Route of Administration, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key company market share analysis, 2023
    • 8.2.3. Pfizer
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Novartis
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Mylan
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Baxter International
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Sanofi
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. GlaxoSmithKline
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Mayne Pharma
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Upsher-Smith Laboratories
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Amomed Pharma
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Merck
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 North America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 4 North America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 North America Antiarrhythmic Drugs Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 7 U.S. Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 10 Canada Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 Canada Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 Mexico Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 16 Europe Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Europe Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Europe Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 Germany Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Germany Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 UK Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 23 UK Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 UK Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 France Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 France Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 France Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 29 Italy Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Italy Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Spain Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 Spain Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 35 Denmark Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Sweden Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Sweden Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Norway Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Norway Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 China Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 48 China Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 China Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Japan Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Japan Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 India Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 India Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 India Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 57 South Korea Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Korea Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Australia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Australia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Thailand Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 Thailand Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Latin America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Latin America Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 70 Brazil Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Brazil Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 73 Argentina Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Argentina Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 76 MEA Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 77 MEA Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 MEA Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 80 South Africa Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 South Africa Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 86 UAE Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 UAE Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antiarrhythmic Drugs Market: Market Outlook
  • Fig. 14 Antiarrhythmic Drugs Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Antiarrhythmic Drugs Market Driver Impact
  • Fig. 18 Antiarrhythmic Drugs Market Restraint Impact
  • Fig. 19 Antiarrhythmic Drugs Market Strategic Initiatives Analysis
  • Fig. 20 Antiarrhythmic Drugs Market: Drug Class Movement Analysis
  • Fig. 21 Antiarrhythmic Drugs Market: Drug Class Outlook And Key Takeaways
  • Fig. 22 Sodium Channel Blockers market estimates and forecast, 2018 - 2030
  • Fig. 23 Beta Blockers market estimates and forecast, 2018 - 2030
  • Fig. 24 Potassium Channel Blockers market estimates and forecast, 2018 - 2030
  • Fig. 25 Calcium Channel Blockers market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
  • Fig. 28 Antiarrhythmic Drugs Market: Route of Administration Outlook And Key Takeaways
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030
  • Fig. 30 Parenteral market estimates and forecast, 2018 - 2030
  • Fig. 31 Other market estimates and forecast, 2018 - 2030
  • Fig. 32 Antiarrhythmic Drugs Market: Distribution Channel Movement Analysis
  • Fig. 33 Antiarrhythmic Drugs Market: Distribution Channel Outlook And Key Takeaways
  • Fig. 34 Hospital Pharmacies market estimates and forecast, 2018 - 2030
  • Fig. 35 Retail Pharmacies market estimates and forecast, 2018 - 2030
  • Fig. 36 Other market estimates and forecast, 2018 - 2030
  • Fig. 37 Antiarrhythmic Drugs Market: Regional Movement Analysis
  • Fig. 38 Antiarrhythmic Drugs Market: Regional Outlook And Key Takeaways
  • Fig. 39 Antiarrhythmic Drugs market share and leading players
  • Fig. 40 North America, by country
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Mexico key country dynamics
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Market share of key market players- Antiarrhythmic Drugs market